Maekawa Shinya, Enomoto Nobuyuki
First Department of Internal Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan.
J Gastroenterol. 2009;44(10):1009-15. doi: 10.1007/s00535-009-0126-7.
Hepatitis C virus (HCV) is a single-stranded RNA virus known for its high genetic variability owing to the lack of a proofreading mechanism of its RNA dependent RNA polymerase. Until now, numerous studies have been undertaken to clarify the correlation between pretreatment HCV genetic variability and the therapeutic response. Even with the recent combination therapy of peginterferon plus ribavirin for chronic hepatitis C, viral response is variable, and only half of treated patients could clear the virus [sustained viral response (SVR)]. In this review, the contribution of viral genetic variability affecting the treatment outcome is discussed according to each HCV genomic region.
丙型肝炎病毒(HCV)是一种单链RNA病毒,因其RNA依赖的RNA聚合酶缺乏校对机制而具有高度的基因变异性。到目前为止,已经进行了大量研究以阐明治疗前HCV基因变异性与治疗反应之间的相关性。即使近期采用聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎,病毒反应仍存在差异,只有一半的治疗患者能够清除病毒[持续病毒学应答(SVR)]。在这篇综述中,将根据HCV基因组的各个区域讨论影响治疗结果的病毒基因变异性的作用。